Highest-materiality recent filing
VivoSim prices up to $4M public offering, closes initial $3M tranche
Initial closing raised $3M at $1.14/share; 286,557 shares + 2,345,022 pre-funded warrants sold.
VivoSim Labs announces results of 2025 annual meeting; elects directors and ratifies auditor
Douglas Jay Cohen and David Gobel elected as Class II directors with 212,079 and 212,420 votes For, respectively.
VivoSim Labs appoints Tony Lialin as Chief Commercial Officer
Tony Lialin appointed CCO effective Aug 11, 2025; leads go-to-market strategy for NAMkind liver/intestine 3D models.
VivoSim Labs regains compliance with Nasdaq minimum equity and bid price rules
On April 30, 2025, Nasdaq confirmed VivoSim Labs demonstrated compliance with minimum $2.5M stockholders' equity and $1.00 bid price requirements.
Effective April 24, 2025, Organovo Holdings changed its name to VivoSim Labs, Inc. with new ticker symbol VIVS on Nasdaq.
Organovo rebrands as VivoSim Labs, ticker changes to VIVS effective April 24
Company to carry forward 3D bioprinting and legacy technology as VivoSim Labs, Inc.
Organovo reports ~$11.3M cash, expects to meet Nasdaq listing requirements
Preliminary cash and equivalents ~$11.3M as of March 31, 2025; Q4 net cash utilization ~$2.0M-$2.2M.
Organovo closes FXR program sale to Lilly; expects reduced spend and runway into FY2026
FXR program sold to Lilly; upfront payments received with future milestone payments anticipated.
Organovo closes sale of FXR program to Lilly for $10M upfront plus up to $50M milestones
Sale of FXR program including lead asset FXR314 to Eli Lilly completed on March 25, 2025.
Organovo implements 1-for-12 reverse stock split to regain Nasdaq minimum bid price compliance
Reverse stock split at ratio 1-for-12, effective March 20, 2025, to combine every 12 shares into 1.
Organovo announces 1-for-12 reverse stock split effective March 20, 2025 to regain Nasdaq compliance
1-for-12 reverse stock split effective 5:00 p.m. ET on March 20, 2025; adjusted trading begins March 21.
Organovo issues ~3M shares via warrant exercises and ATM sales, raising ~$2.3M
Issued 2,967,144 shares of common stock from warrant exercises and at-the-market sales.
Organovo sells FXR program to Eli Lilly for $10M upfront; faces Nasdaq delisting
Lilly to buy Organovo's FXR program for $10M upfront ($9M at close, $1M escrow) + up to $50M in milestones.
Nasdaq notified Organovo on Jan 16, 2025 that it failed to regain compliance with $1 minimum bid price rule.
Organovo names Norman Staskey President and CFO; Tomas Hess resigns for retirement
Tomas Hess resigned as President, CFO effective Dec 24, 2024 to pursue retirement; no disagreement on accounting policies.
Organovo shareholders approve reverse stock split (1:5-1:20) and 1.78M share equity plan increase
Reverse stock split authorized at ratio 1-to-5 to 1-to-20, board discretion until Nov 20, 2025; 88.64% voted for.
Organovo grants Chairman Murphy options on ~1M shares at $0.5368, vesting over 3 years
Time-based option for 574,923 shares vests 1/3 annually over 3 years subject to continued service.
Organovo received Nasdaq delisting notice for bid price below $1 per share
Nasdaq notice on July 18, 2024: closing bid price below $1 for 30 consecutive business days.
Organovo prices $5.25M public offering of common stock and warrants
Offering of 6.56M units at $0.80/unit; gross proceeds $5.25M before expenses.
Organovo furnishes May 2024 corporate presentation; no specific financial data disclosed
Company posted investor presentation on its website covering business overview and strategy.
Organovo issues 1.35M shares for ~$1.8M under ATM facility
Issued 1,349,778 shares between Feb 1 and Apr 19, 2024; gross proceeds of $1.8 million.
Organovo presents FXR314 data in 3D models of Crohn's disease and ulcerative colitis
FXR314, a clinical-stage FXR agonist, tested in human primary cell 3D models.
On March 21, 2025, Vaidehi Joshi notified the Board of Directors (the "Board") of the Company that she resigned from the Board and all committees of the Board, effective as of March 21, 2025.
Max materiality 0.80 · Median 0.60 · Most common event other_material